MBX Biosciences Inc
MBX Biosciences Inc (MBX) Historical Volatility
MBX 30-day historical volatility is 35%. This ranks in the 2th percentile of readings over the past year.
Read more
Tracking MBX historical volatility helps you see how much MBX Biosciences Inc's stock price has actually moved over past periods, giving you a baseline to judge whether current option premiums are fair, cheap, or expensive. While implied volatility tells you what the market expects, MBX Biosciences Inc's HV tells you what really happened. Use our scanner to monitor MBX 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of an underlying's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. The MBX 30 day historical volatility is one of the most widely watched readings because it balances responsiveness with stability. Comparing MBX Biosciences Inc's HV to its implied volatility reveals the volatility risk premium — when IV sits well above HV, option sellers tend to have an edge; when HV runs hot relative to IV, buyers may be underpaying for movement.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery.
In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Sizing a long premium trade, modeling a covered call, or hunting volatility arbitrage all come back to one question: how much has the stock actually moved? Our scanner puts MBX Biosciences Inc's historical volatility side-by-side with implied readings across every lookback window, so you can see exactly where MBX HV is running hot, cold, or in line. Make the MBX 30 day historical volatility — and every other window — work for your edge instead of against it.
As of September 22, 2026
As of September 22, 2026
See how volatility has moved over time
Track MBX historical volatility, spot where IV and realized volatility diverge, and find options that are priced in your favor right now.
Start your 14-day free trial→